Three names dominate the longevity supplement conversation in every podcast, clinic, and biohacker forum: NMN, NR, and resveratrol. They have different mechanisms, different evidence bases, and different risk profiles. This guide cuts through the noise with a side-by-side comparison grounded in human trial data — not rodent studies, not influencer claims.
We'll tell you what each compound actually does, what the human evidence shows, how to stack them intelligently, and who genuinely benefits. If you want a shortcut, jump to the comparison table below. If you want to understand the science, read every section.
Two of these three supplements — NMN and NR — exist specifically to raise NAD+ (nicotinamide adenine dinucleotide), a coenzyme present in every cell that sits at the center of energy metabolism, DNA repair, and sirtuin activation. The third, resveratrol, activates the same sirtuin enzymes that NAD+ feeds.
NAD+ declines roughly 1–2% per year after your 30s. By age 60, most people are operating at roughly half the NAD+ levels they had at 20. This decline correlates — though does not fully cause — slower metabolism, reduced mitochondrial efficiency, impaired DNA repair, and blunted stress response pathways.
The hypothesis underlying both NMN and NR supplementation is straightforward: restore NAD+ levels toward youthful ranges, and the downstream biology improves. Resveratrol operates differently — it doesn't raise NAD+ directly but amplifies SIRT1 activation, a NAD+-dependent enzyme involved in cellular stress resistance and fat metabolism.
Whether these mechanisms translate to meaningful longevity benefits in humans is the real question — and the honest answer in 2026 is: promising, but not conclusive. Here is what the evidence actually shows.
| Factor | NMN | NR (Nicotinamide Riboside) | Resveratrol |
|---|---|---|---|
| Primary mechanism | NAD+ precursor via NMN → NAD+ pathway; enters cells directly | NAD+ precursor via NR → NMN → NAD+ pathway; well-absorbed | SIRT1/SIRT3 activator; polyphenol; indirect NAD+ pathway via AMPK |
| Human RCT evidence strength | Moderate — NAD+ elevation confirmed; functional benefits emerging | Moderate-strong — most replicated NAD+ elevation data of the three | Mixed — bioavailability challenges limit translation; anti-inflammatory data stronger |
| Typical daily dose | 250–500 mg (some researchers use 1,000 mg) | 250–500 mg (standard clinical doses) | 150–500 mg trans-resveratrol (with fat for absorption) |
| Estimated monthly cost | $40–$80 for quality 500 mg/day | $40–$70 for quality 300 mg/day | $20–$50 for 200–500 mg/day |
| Synergistic with | Resveratrol, TMG (methyl donor), exercise | Resveratrol, pterostilbene, exercise | NMN or NR (SIRT1 needs NAD+ substrate), quercetin, fat-containing meal |
| Best profile for | Adults 40+ focused on metabolic health, muscle function, NAD+ optimization | Adults 35+ seeking well-studied NAD+ support; good first NAD+ precursor | Adults interested in cardiovascular, metabolic, and anti-inflammatory benefits; works best added to an NMN or NR base |
Evidence bars below reflect the relative strength of human randomized controlled trial data specifically — not animal studies, observational data, or mechanistic in vitro research.
NAD+ elevation is consistently demonstrated. Functional outcomes (muscle endurance, insulin sensitivity, sleep) are promising but require larger trials to confirm effect sizes.
NR has the deepest human trial record of the three. NAD+ elevation is well replicated. Cardiovascular and metabolic benefits emerging; long-term longevity outcomes not yet established in humans.
Extensive in vitro and animal data. Human trials show anti-inflammatory and cardiovascular signals, but poor oral bioavailability limits consistency. Formulation matters enormously here.
NMN is one step closer to NAD+ than NR in the biosynthesis pathway. It enters cells via a dedicated transporter (Slc12a8) discovered in 2019, bypassing the NR → NMN conversion step. This is the primary argument for NMN over NR among researchers who favor it.
A 2021 randomized controlled trial published in Science found that 250 mg/day of NMN increased skeletal muscle NAD+ levels and improved muscle insulin sensitivity in older women. A 2022 trial in Nature Aging (Imai group, Washington University) demonstrated that 500 mg/day raised blood NAD+ and improved aerobic capacity in recreational runners. Subsequent trials from Japan have shown benefits in fatigue reduction and sleep quality.
The honest limitation: most NMN trials are small (20–60 participants), short (8–12 weeks), and have not yet demonstrated long-term outcomes like reduced disease incidence or mortality. The blood NAD+ elevation is real and consistent. Whether it translates to meaningful longevity extension in humans is genuinely unknown.
The most studied range is 250–500 mg/day. Some longevity physicians (including David Sinclair, who is not a doctor treating patients but a researcher) have publicly discussed taking 1,000 mg/day, though this exceeds the doses studied in most RCTs. Morning dosing is most common. Take with or without food — absorption appears adequate either way.
Human trials to date show a clean safety profile at doses up to 1,200 mg/day in short-duration studies. No serious adverse events have been reported. Mild nausea at high doses occurs in some individuals.
View NMN on Amazon →Look for stabilized NMN (often beta-NMN) in airtight, dark packaging. Third-party tested brands are strongly preferred given the market's quality variance.
NR (nicotinamide riboside) is the most extensively human-trialed NAD+ precursor available today. It was commercialized earlier than NMN — primarily through the Tru Niagen brand, which has sponsored a significant portion of the clinical research — which gives it a longer published record.
NR reliably raises whole-blood and tissue NAD+ levels within days at doses of 300–500 mg/day. A 2018 study in Nature Communications (University of Colorado) found 500 mg/day of NR reduced aortic stiffness in healthy older adults. Multiple trials have demonstrated reductions in inflammatory markers. A 2020 trial showed NR reduced hepatic fat in NAFLD patients.
NR also has a small but growing record in clinical populations — Parkinson's disease patients showed brain NAD+ increases in a 2019 trial. This kind of tissue-specific data in disease populations is ahead of NMN's current trial record.
The honest answer is we don't know yet. Head-to-head human comparison trials are limited. NR has more replication. NMN may have a more direct cellular uptake route. Both raise NAD+ effectively. If you're starting with a NAD+ precursor and want the most studied option, NR is a defensible first choice. If you want the compound with the most momentum in recent research, NMN is reasonable.
Standard clinical doses are 250–500 mg/day. Morning dosing is standard. NR is stable at room temperature and does not require refrigeration in most formulations.
View NR (Nicotinamide Riboside) on Amazon →Tru Niagen (ChromaDex) is the category's reference product with the most clinical backing. Third-party tested generics are also available at lower price points.
Resveratrol operates on a different axis than NMN and NR. Rather than being a NAD+ precursor, it is a SIRT1 activator — it makes the sirtuin enzyme work more efficiently when NAD+ is present. Think of NAD+ as the fuel and resveratrol as a throttle that opens the engine wider.
The initial excitement around resveratrol came from David Sinclair's 2003 research showing it activated sirtuins and extended lifespan in yeast, and subsequent animal work showing remarkable effects in obese mice. That animal data did not translate cleanly to humans — but resveratrol is not without human evidence.
The most consistent human signals from resveratrol are in:
The bioavailability problem is real: standard trans-resveratrol is rapidly metabolized and cleared. Only about 1% of an oral dose reaches systemic circulation unchanged. Newer formulations using micronized, liposomal, or phospholipid-complexed resveratrol show improved bioavailability — look for these on the label.
Most positive human trials used 150–500 mg/day of trans-resveratrol, taken with a fat-containing meal to improve absorption. Some researchers use 1,000 mg/day without clear additional benefit over 500 mg in humans. Always take with food — absorption increases approximately 2–3x with dietary fat.
View Resveratrol on Amazon →Specify trans-resveratrol (not cis-resveratrol, the inactive isomer). Micronized or phospholipid-complexed formulations offer better bioavailability. Check for third-party purity certificates.
The combination of NMN (or NR) with resveratrol has theoretical elegance: raise the NAD+ substrate with NMN/NR, then amplify SIRT1 activity with resveratrol. The enzyme gets more fuel and a more efficient engine simultaneously.
David Sinclair has discussed taking this combination for years, and it has become the most popular longevity stack by volume. The mechanistic rationale is sound. The human clinical data specifically on the combination is thin — most trials test compounds in isolation.
What we can say: the compounds do not appear to interact negatively. They operate on compatible and potentially additive pathways. Many longevity clinicians recommend the combination precisely because the downside risk of combining them appears low while the theoretical upside is meaningful.
If you add only one thing to an existing NMN or NR routine, resveratrol is the most logical addition based on current mechanistic understanding — particularly if your goals include cardiovascular protection and metabolic health alongside NAD+ optimization.
A related compound worth knowing: pterostilbene is a methylated resveratrol analogue with substantially better bioavailability (80%+ oral absorption vs. resveratrol's ~1%). Some practitioners have shifted toward pterostilbene as a resveratrol replacement. It has less human trial data but a more favorable pharmacokinetic profile.
Either NMN or NR makes sense as a base. NR has the longer published safety and efficacy record. NMN has more recent momentum. Add resveratrol if budget allows, particularly if cardiovascular health is a priority. Take with fat at breakfast.
NMN at 500 mg/day is the choice most longevity physicians recommend in this age group, based on the Imai/Washington University research in older adults showing metabolic improvements. Stack with resveratrol 200–400 mg and ensure you're also supplementing TMG (trimethylglycine) as a methyl donor — high NMN doses can deplete methyl groups over time.
Choose NR — specifically a product using ChromaDex's NIAGEN ingredient. It has the most replicated human trial record and the best-documented safety profile of the three compounds reviewed here.
Resveratrol alone is defensible, particularly if budget limits you to one compound. Use a high-quality trans-resveratrol or pterostilbene formulation, always with a fat-containing meal. The cardiovascular signal from human trials is more consistent than the longevity/NAD+ signal.
Exercise — particularly Zone 2 cardio and resistance training — raises NAD+ more robustly than any supplement studied to date. Caloric restriction mimetics like fasting activate sirtuins. These interventions have decades of human outcome data. Supplements are adjuncts, not replacements.
NAD+ Precursor: NMN 500 mg or NR 300–500 mg — take on waking or with breakfast
SIRT1 Activator: Trans-resveratrol 200–400 mg — take with fat-containing meal (eggs, avocado, olive oil) for 2–3x better absorption
Methyl Donor (if using NMN >500 mg): TMG (trimethylglycine) 500–1,000 mg — prevents SAM-e depletion from high NMN throughput
Frequency: Daily. Some practitioners cycle 5 days on / 2 days off — the evidence for this over daily dosing is weak but there is no demonstrated harm.
If you are going to take any of these three compounds, here is the clearest summary of where the evidence lands in 2026:
For broader context on how these compounds fit into a complete longevity supplement framework, see our guide to the best longevity supplement brands. For an adjacent compound with surprisingly robust data in adults over 40, read our deep dive on creatine for people over 40 — it has a stronger human outcome record than any of the three compounds reviewed here.
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.